SAN DIEGO, April 29, 2021 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr.
Helen Torley, president and chief
executive officer, will present virtually at the BofA Securities
2021 Virtual Health Care Conference on Tuesday, May 11,
2021 at 12:30 p.m. Eastern Time / 9:30 a.m.
Pacific Time
An audio-only direct link of the presentation can be accessed
through the "Investors" section of www.halozyme.com, and a
recording will be made available for 6 months following the event.
To access the link, please visit Halozyme's website approximately
10 minutes prior to the presentation to register and download any
necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. Halozyme advises and
supports its biopharmaceutical partners in key aspects of new drug
development with the goal of improving patients' lives while
helping its partners achieve global commercial success. As the
innovators of the ENHANZE® technology, which can reduce
hours-long treatments to a matter of minutes, Halozyme's
commercially-validated solution has positively impacted more than
400,000 patient lives via five commercialized products across more
than 100 global markets. Halozyme and its world-class partners are
currently advancing multiple therapeutic programs intended to
deliver innovative therapies, with the potential to improve the
lives of patients around the globe. Halozyme's proprietary enzyme
rHuPH20 forms the basis of the ENHANZE® technology and
is used to facilitate the delivery of injected drugs and fluids,
potentially reducing the treatment burden of other drugs to
patients. Halozyme has licensed its ENHANZE® technology
to leading pharmaceutical and biotechnology companies including
Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers
Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives
revenues from these collaborations in the form of milestones and
royalties as the Company's partners make progress developing and
commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-present-at-bofa-securities-2021-virtual-health-care-conference-301280667.html
SOURCE Halozyme Therapeutics, Inc.